We’re launching Lyria 3.5 in Google Flow Music, with advances across musicality, lyrics, vocals, and creative control
deepmind.google·6d ago
AI Engineering
Hacker News·17d ago·5 min read
FDA approves new kind of cholesterol pill
TL;DR
Adults with high cholesterol now have a new treatment option with Lipfendra, the first oral PCSK9 inhibitor. This daily tablet complements diet and exercise to lower LDL cholesterol levels.
✦ Why It Matters
Consider integrating Lipfendra into treatment plans for patients struggling with high LDL cholesterol levels.
Key Takeaways
- Explore Lipfendra as a treatment option for patients with high LDL cholesterol.
- Monitor patients for common side effects like diarrhea and dizziness.
- Stay updated on new cardiovascular therapies and their implications.
- Encourage routine cholesterol testing for early detection of hypercholesterolemia.
Full Summary
Lipfendra (enlicitide) is the first oral medication that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9), a protein that regulates cholesterol levels. Approved by the FDA, it is intended for adults with hypercholesterolemia, particularly those who have not achieved adequate cholesterol reduction with existing therapies.
In clinical trials involving over 3,200 adults, Lipfendra demonstrated an average LDL cholesterol reduction of 56% in patients with established cardiovascular disease and 59% in those with heterozygous familial hypercholesterolemia after 24 weeks of treatment. Adverse reactions were similar to placebo, with diarrhea and dizziness being the most common side effects.
This approval highlights ongoing advancements in managing chronic cardiovascular diseases, addressing a major risk factor for heart attacks and strokes.